MeSH term
Frequency | Condition_Probility | Humans | 75 | 0.0 |
Kinetics | 3 | 0.0 |
Protein Binding | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 16 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Incidence | 7 | 0.0 |
Multivariate Analysis | 6 | 0.0 |
Prospective Studies | 9 | 0.0 |
Risk Factors | 21 | 0.0 |
*Tuberculin Test | 19 | 67.0 |
Contact Tracing | 2 | 33.0 |
Tuberculin Test | 14 | 26.0 |
Adolescent | 28 | 0.0 |
Adult | 49 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Child | 13 | 0.0 |
Child, Preschool | 14 | 0.0 |
Female | 48 | 0.0 |
Logistic Models | 6 | 0.0 |
Male | 47 | 0.0 |
Odds Ratio | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 29 | 0.0 |
Tuberculosis, Pulmonary/*transmission | 3 | 100.0 |
Sex Hormone-Binding Globulin/metabolism | 2 | 0.0 |
United States | 2 | 0.0 |
Comparative Study | 14 | 0.0 |
Mass Screening | 4 | 2.0 |
Middle Aged | 34 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Aged | 24 | 0.0 |
Aged, 80 and over | 13 | 0.0 |
BCG Vaccine | 4 | 40.0 |
Interferon Type II/*blood | 2 | 6.0 |
Lymphocyte Activation | 2 | 0.0 |
Mycobacterium tuberculosis/*isolation & purification | 2 | 33.0 |
Tuberculosis/*diagnosis | 3 | 60.0 |
English Abstract | 8 | 0.0 |
*Students, Nursing | 2 | 100.0 |
California/epidemiology | 3 | 7.0 |
Case-Control Studies | 3 | 0.0 |
False Positive Reactions | 2 | 0.0 |
Tuberculin Test/*statistics & numerical data | 5 | 100.0 |
Age Factors | 7 | 0.0 |
Cohort Studies | 5 | 0.0 |
Infant | 11 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
New York City/epidemiology | 3 | 8.0 |
Electric Stimulation/methods | 2 | 7.0 |
Evoked Potentials, Motor | 2 | 22.0 |
Multiple Sclerosis/*physiopathology | 2 | 15.0 |
Statistics, Nonparametric | 2 | 0.0 |
Spain/epidemiology | 2 | 1.0 |
Tuberculosis/*epidemiology | 4 | 66.0 |
Urban Population | 2 | 1.0 |
*Mass Screening | 2 | 3.0 |
Prevalence | 10 | 0.0 |
Program Evaluation | 2 | 4.0 |
Brain/physiopathology | 2 | 3.0 |
BCG Vaccine/administration & dosage | 2 | 25.0 |
Double-Blind Method | 2 | 0.0 |
Tuberculin Test/*methods | 3 | 42.0 |
Time Factors | 6 | 0.0 |
Tuberculosis/diagnosis/*epidemiology | 3 | 60.0 |
*Cross Infection | 2 | 50.0 |
*Personnel, Hospital | 2 | 40.0 |
Sex Factors | 3 | 0.0 |
Emigration and Immigration | 2 | 4.0 |
Questionnaires | 5 | 0.0 |
Tuberculin Test/*utilization | 2 | 100.0 |
*BCG Vaccine | 3 | 50.0 |
Botswana/epidemiology | 2 | 66.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Tuberculosis/*diagnosis/epidemiology/prevention & control | 2 | 100.0 |
Mycobacterium tuberculosis/isolation & purification | 3 | 13.0 |
*Travel | 3 | 11.0 |
Patient Compliance | 2 | 1.0 |
Treatment Outcome | 2 | 0.0 |
Skin Tests | 2 | 1.0 |
Cross-Sectional Studies | 6 | 0.0 |
HIV Infections/*complications | 2 | 0.0 |
False Negative Reactions | 2 | 1.0 |
Retrospective Studies | 6 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Animals | 2 | 0.0 |
Age Distribution | 2 | 0.0 |
Probability | 3 | 0.0 |
Risk Assessment | 3 | 0.0 |
Likelihood Functions | 2 | 1.0 |
*Contact Tracing | 2 | 66.0 |
Occupational Exposure | 2 | 2.0 |
Testosterone/*metabolism | 2 | 5.0 |
*Bacterial Toxins | 5 | 3.0 |
Enterotoxins/*immunology | 2 | 2.0 |
Longitudinal Studies | 2 | 0.0 |
*Superantigens | 5 | 11.0 |
Bacteriological Techniques | 2 | 8.0 |
Cells, Cultured | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Vaccination | 2 | 1.0 |
BCG Vaccine/*administration & dosage/immunology | 2 | 100.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
In Vitro | 2 | 0.0 |
